J Hematol Oncol
J Hematol Oncol
Country: Unknown
Publisher: Unknown
Publication Period: Unknown
947
Papers in Database
Journal Information
Publication Details
Additional Information
Subject Term Count: 1
Last Updated: Aug 05, 2025
Recent Papers
View All 947 PapersFFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z, Qin J, Qian Y, Huang C, Liu X, Wang N, Li L, Chao Y, Tan B, Zhang N, Qian M, Li D, Liu M, D…
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications.
Zhao B, Wu B, Feng N, Zhang X, Zhang X, Wei Y, Zhang W.
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to e…
Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, Wang Y, Wang T, Xiang J, Wang B.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after…
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, …
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Li Y, Liu J, Chen W, Wang W, Yang F, Liu X, Sheng Y, Du K, He M, Lyu X, Li H, Zhao L, Wei Z, Wang F…
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K, Banday AR.
Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CA…
Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, Epperla N.
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A, Álvarez-Vallina L, Sanz L.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de R…
Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X.